Sanofi reaps first fruit of Abl­ynx buy­out with a Eu­ro­pean OK for its lead rare dis­ease drug

Just weeks af­ter clos­ing its $4.8 bil­lion ac­qui­si­tion of Abl­ynx, Sanofi has bagged a Eu­ro­pean ap­proval for its lead drug, capla­cizum­ab, which treats an …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.